Healthcare utilization and costs among patients with acromegaly in the United States
Journal of Comparative Effectiveness Research · 2025
DOI: 10.57264/cer-2025-0069 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Comparative Effectiveness Research, 2025. Verfasst von Tiffany P Quock und 8 weiteren Autor:innen. Beteiligte Einrichtung: Crinetics Pharmaceuticals, San Diego, CA 92121, USA. Hauptthemen laut MEDLINE: Acromegaly, Patient Acceptance of Health Care, Health Care Costs. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Aim
Recent evidence regarding the healthcare resource utilization (HCRU) and associated costs of acromegaly is limited. Materials & methods: This retrospective, cross-sectional administrative claims analysis (IQVIA Pharmetrics Plus ® ) identified patients (≥18 years) with acromegaly between 1 January 2017 and 30 June 2022. HCRU and costs over 1 year were compared in patients with acromegaly and matched patients without acromegaly (age, sex, insurance type, year). Among patients with acromegaly, annual total healthcare costs of comorbidities and procedures consistent with high-risk comorbidities were reported. Costs were adjusted to 2023 USD.
Results
Among 2289 patients with acromegaly and 2289 matched patients without acromegaly, mean age was 49.8 years and 51.6% were female. Patients with acromegaly had a significantly (p < 0.001) higher comorbidity burden than patients without acromegaly. A significantly (p < 0.001) greater proportion of patients with acromegaly versus patients without acromegaly had inpatient hospitalizations (20.1 vs 4.9%) and emergency department visits (23.9 vs 15.7%). Total mean healthcare costs were also significantly higher for patients with acromegaly than patients without acromegaly ($51,888 vs $10,601). The majority of acromegaly-related healthcare costs ($30,985) were attributable to acromegaly therapy ($25,895). Hypertension (42.8%) was the most common high-risk comorbidity associated with acromegaly. The costliest high-risk comorbidity was congestive heart failure, with a mean cost difference of $38,123 (p < 0.05) between patients with acromegaly with and without hypertension.
Conclusion
Patients with acromegaly had higher HCRU and costs than matched patients without acromegaly, and the presence of acromegaly with high-risk comorbidities was associated with a substantial HCRU and cost burden. This high burden of illness may be alleviated with better disease control.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Crinetics Pharmaceuticals, San Diego, CA 92121, USA.
- ADVI Health, LLC, Washington, DC 20004, USA.
ORCID-Profile: Tiffany P Quock, Eunice Chang, Ashis K Das, Amanda Speller, Marian H Tarbox, Melinda L Rossi, Stacy K Rattana, Ingrid E Paulson, Michael S Broder
Zitieren
APA
Quock, T. P., Chang, E., Das, A. K., Speller, A., Tarbox, M. H., Rossi, M. L., Rattana, S. K., Paulson, I. E., & Broder, M. S. (2025). Healthcare utilization and costs among patients with acromegaly in the United States. Journal of Comparative Effectiveness Research. https://doi.org/10.57264/cer-2025-0069
Vancouver
Quock TP, Chang E, Das AK, Speller A, Tarbox MH, Rossi ML, et al. Healthcare utilization and costs among patients with acromegaly in the United States. Journal of Comparative Effectiveness Research. 2025. doi:10.57264/cer-2025-0069
BibTeX
@article{Quock2025,
author = {Quock, Tiffany P and Chang, Eunice and Das, Ashis K and Speller, Amanda and Tarbox, Marian H and Rossi, Melinda L and Rattana, Stacy K and Paulson, Ingrid E and Broder, Michael S},
title = {Healthcare utilization and costs among patients with acromegaly in the United States},
journal = {Journal of Comparative Effectiveness Research},
year = {2025},
doi = {10.57264/cer-2025-0069}
}
EUVIMED